We provide you with 20 years of free, institutional-grade data for ACRS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ACRS. Explore the full financial landscape of ACRS stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$1,400,145
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Mehra Anand | Derivatives Exercise | 11,580 | 2026-06-08 | ||
| Humphries William D. | Derivatives Exercise | 11,580 | 2026-06-08 | ||
| Molineaux Christopher P. | Derivatives Exercise | 11,580 | 2026-06-08 | ||
| MILANO VINCENT | Derivatives Exercise | 11,580 | 2026-06-08 | ||
| GOWEN MAXINE | Derivatives Exercise | 11,580 | 2026-06-08 | ||
| SCHIFF ANDREW N | Derivatives Exercise | 11,580 | 2026-06-08 | ||
| Hall Jesse Wayne | Sale | -9,330 | $4.41 | $41,145 | 2026-05-05 |
| Hall Jesse Wayne | Derivatives Exercise | 36,375 | 2026-05-05 | ||
| Leonard Braden Michael | Sale | -300,000 | $4.53 | $1,359,000 | 2026-04-27 |
| Balthaser Kevin | Sale | -677 | $2.87 | $1,943 | 2026-03-03 |
| Balthaser Kevin | Derivatives Exercise | 2,375 | 2026-03-03 | ||
| Walker Neal | Sale | -18,611 | $3.47 | $64,580 | 2026-02-05 |
| Walker Neal | Derivatives Exercise | 63,475 | 2026-02-05 | ||
| Davis Hugh M. | Derivatives Exercise | 18,675 | 2026-02-05 | ||
| Balthaser Kevin | Sale | -6,449 | $3.47 | $22,378 | 2026-02-05 |
| Balthaser Kevin | Derivatives Exercise | 22,025 | 2026-02-05 | ||
| Loerop James | Sale | -16,623 | $3.51 | $58,347 | 2026-02-05 |
| Loerop James | Derivatives Exercise | 54,375 | 2026-02-05 | ||
| Balthaser Kevin | Sale | -4,984 | $3.51 | $17,494 | 2026-02-03 |
| Balthaser Kevin | Derivatives Exercise | 14,750 | 2026-02-03 | ||
| Loerop James | Sale | -31,960 | $2.48 | $79,261 | 2026-02-03 |
| Loerop James | Sale | -40,165 | $3.01 | $120,897 | 2026-01-05 |
| Loerop James | Derivatives Exercise | 91,900 | 2026-01-05 | ||
| Balthaser Kevin | Sale | -26,645 | $3.01 | $80,201 | 2026-01-05 |
| Balthaser Kevin | Derivatives Exercise | 94,450 | 2026-01-05 | ||
| Walker Neal | Sale | -9,952 | $2.88 | $28,662 | 2026-01-05 |
| Walker Neal | Derivatives Exercise | 29,150 | 2026-01-05 | ||
| Davis Hugh M. | Derivatives Exercise | 26,750 | 2025-12-04 | ||
| MILANO VINCENT | Derivatives Exercise | 4,793 | 2025-06-09 | ||
| Mehra Anand | Derivatives Exercise | 4,793 | 2025-06-09 | ||
| Humphries William D. | Derivatives Exercise | 4,793 | 2025-06-09 | ||
| GOWEN MAXINE | Derivatives Exercise | 4,793 | 2025-06-09 | ||
| Molineaux Christopher P. | Derivatives Exercise | 4,793 | 2025-06-09 | ||
| SCHIFF ANDREW N | Derivatives Exercise | 4,793 | 2025-06-09 |
The information provided in this report about ACRS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Aclaris Therapeutics, Inc(NASDAQ:ACRS) 
Aclaris Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. The Company operates in two segments, Therapeutics and Contract Research. Its products pipeline includes ATI-450, an investigational or...
Website: http://www.aclaristx.com
Founded: 2012
Full Time Employees: 75
Sector: Healthcare
Industry: Biotechnology